BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 26, 2006
View Archived Issues
DOV Shares Crushed After Phase III Bicifadine Failure
Poor Phase III data nearly halved DOV Pharmaceutical Inc.'s stock value Tuesday after the findings were unveiled late Monday. (BioWorld Today)
Read More
Millipore Paying $1.4B In Cash To Buy Serologicals
Read More
Discovery Lab's Stock Crashes On News Of Surfaxin Problem
Read More
Light Sciences Oncology Files To Raise $86M In IPO
Read More
Clinic Roundup
Read More
Other News To Note
Read More